Peptide DNA Testing: Can Your Genome Tell You Which Peptides Will Actually Work?

Open any biohacking forum and you will find the same pattern repeated thousands of times. One person tries BPC-157 and calls it life-changing. Another tries the exact same protocol at the same dose and reports nothing at all. One person on GHK-Cu sees a dramatic improvement in skin quality within a month. Someone else sees a mild benefit after three. One person tolerates semaglutide with no issues. Another has to quit after a week of intolerable nausea.

The obvious explanation is dose, purity, or placebo. Those explanations cover some of the variance but not all of it. The remaining variance lives in your genome.

Every peptide acts on a receptor, is transported by a carrier protein, and is metabolised by an enzyme. Each of those proteins is encoded by a gene. Your gene variants (known as single nucleotide polymorphisms, or SNPs) determine how well those proteins work in your body. Two people with different variants of the same gene can respond to the same peptide dose in completely different ways.

This is not new science. It is the foundation of pharmacogenomics — the field that already guides drug selection for depression, blood thinners, and cancer chemotherapy in hospital medicine. What is new is the possibility of applying the same approach to the peptide space.

For conventional drugs, pharmacogenomic testing is mainstream. The US FDA lists over 450 drugs with documented pharmacogenomic associations. Warfarin dosing is routinely adjusted based on CYP2C9 and VKORC1 variants. SSRI selection for depression is guided by CYP2D6 and CYP2C19 metaboliser status. Abacavir is contraindicated in people carrying the HLA-B*5701 allele because of a specific hypersensitivity risk.

The same genes and enzymes also act on peptides. The CYP450 enzyme family metabolises many peptides alongside small-molecule drugs. The melanocortin receptor family (MC1R, MC4R) has variants that dramatically change the response to peptides like melanotan and PT-141. The GLP-1 receptor itself (GLP1R) has well-documented SNPs that influence semaglutide and tirzepatide response in published clinical studies.

The peptide space has simply not had the large clinical-trial infrastructure that let pharmacogenomics mature for conventional drugs. But the underlying biology is the same. The gene variants that shape drug response are the same variants that shape peptide response, because the receptors and enzymes involved overlap substantially.

A well-designed peptide DNA analysis looks at several categories of gene variants, each of which changes how a given peptide is likely to work for you.

Receptor variants. The most directly relevant category. GLP1R variants influence response to semaglutide and tirzepatide. MC4R variants influence response to melanotan-2 and PT-141. Growth hormone secretagogue receptor (GHSR) variants influence response to ipamorelin and CJC-1295. Vitamin D receptor (VDR) variants interact with many longevity peptides. Even small differences in receptor structure can meaningfully change binding affinity and downstream signalling.

Metaboliser variants. The CYP450 enzymes (CYP3A4, CYP2D6, CYP1A2, CYP2C9, CYP2C19) determine how quickly peptides and their breakdown products are cleared. A fast metaboliser may need a higher dose for the same effect. A slow metaboliser is at higher risk for side effects at standard doses.

Collagen and skin pathway variants. For peptides targeting skin and connective tissue (GHK-Cu, TB-500, BPC-157), variants in collagen genes (COL1A1, COL3A1), MMPs (matrix metalloproteinases), and antioxidant enzymes (SOD2, GPX1) shape how much benefit you are likely to see.

Metabolic and insulin pathway variants. For weight-loss and metabolic peptides, variants in FTO, MC4R, PPARG, TCF7L2, and adiponectin genes (ADIPOQ) strongly predict both baseline obesity risk and response to GLP-1 agonists.

Methylation and detoxification variants. MTHFR, COMT, and GST variants affect how your body processes intermediates and metabolites. These are particularly relevant for peptides that interact with neurotransmitters (semax, selank) or antioxidant pathways (glutathione peptides).

Mitochondrial haplogroup. Your maternal line determines your mitochondrial DNA, and this in turn shapes baseline mitochondrial function. Haplogroup H has higher baseline ATP efficiency than haplogroup J, for instance. Mitochondrial peptides (SS-31, MOTS-c) act differently depending on this baseline.

If you have already done AncestryDNA, 23andMe, MyHeritage, or a similar consumer DNA test, you already have the raw data needed. The commercial services report a curated summary focused on ancestry or health traits, but the underlying file (usually a compressed .txt or .vcf) contains between 600,000 and 2 million genotyped SNPs. That raw file is downloadable directly from your account.

With the raw file in hand, targeted analysis can extract the specific SNPs that matter for peptide response without any new DNA collection. The privacy model is also better: the raw data never leaves your control if the analysis is performed locally or on ephemeral infrastructure.

This matters because it means a peptide-matching analysis does not require a new saliva kit, a new courier, or another six-week turnaround. For most people who have already done an ancestry test, the genotype data they need is already sitting in their account, waiting to be put to use.

A well-designed peptide DNA report is not a list of SNPs. Raw SNP tables are noise for most people. The useful output is a translated recommendation grounded in the science.

For each peptide in the catalogue, a good report answers three questions. First, is this peptide likely to work well for you given your receptor variants? Second, do you need a dose adjustment based on your metaboliser status? Third, are there specific side effects or interactions you are at elevated risk for?

The report should also make explicit what it is not. It is not a clinical diagnosis. It is not a guarantee that a peptide will or will not work for you — gene variants shift probabilities rather than determining outcomes. It is not a substitute for medical supervision. It is an extra layer of evidence alongside the research literature, your own biomarkers, and any clinical guidance.

What it replaces is the alternative: spending several hundred dollars on a peptide, running an 8 to 12 week protocol, and discovering at the end that your gene variants meant it was never likely to work for you in the first place.

The peptides.fyi Peptide DNA Report is being built as a one-off analysis you can run against your existing AncestryDNA, 23andMe, or equivalent raw data. There is no new sample collection, no saliva kit, and no ongoing subscription. You upload the raw file, the analysis runs, and you receive a personalised report covering the peptides in our catalogue.

The first version will cover the most-researched peptides where the pharmacogenomic evidence is strongest: the GLP-1 family (semaglutide, tirzepatide, retatrutide), the repair peptides (BPC-157, TB-500), the skin and collagen peptides (GHK-Cu), the growth hormone secretagogues (CJC-1295, ipamorelin), and the longevity peptides with mitochondrial mechanisms (SS-31, MOTS-c). Later versions will expand to cover the full peptide catalogue.

The target price at launch is around 49 USD for the one-off report. Waitlist subscribers will receive founder pricing, first access, and a free update when the report expands to cover additional peptides.

We are building this specifically for people who are already spending serious money on peptides and do not want to waste it on stacks that are unlikely to work for them genetically. If that is you, join the waitlist below.

We take DNA privacy seriously because the alternative is genuinely dangerous. Your genome is not a password you can change. Once it is leaked, it is leaked for life.

Our planned approach is the one with the smallest attack surface. Your raw DNA file is uploaded over an encrypted connection, processed for the analysis, and then deleted after the report is generated. Nothing is stored long-term on our servers. Nothing is shared with third parties. Nothing is used to train models or build datasets. We do not need to retain the data to deliver the product, so we do not.

We will publish the full data-handling policy before launch. Anyone who is uncomfortable with uploading DNA data will always have the option not to. The report is a deliberately optional product, not a default.

Do I need a new DNA test? No. If you have raw data from AncestryDNA, 23andMe, MyHeritage, FamilyTreeDNA, Living DNA, or any service that provides a raw data download, that is what the report uses.

What if I do not have a DNA test yet? You can order an AncestryDNA or 23andMe kit directly. Once your results are ready (typically 4 to 8 weeks), download the raw data file and you are set.

Is this medical advice? No. This is a research-grade informational report. It is not a clinical pharmacogenomic test and is not regulated as a medical device. It should be used alongside professional medical advice, not as a substitute for it.

Will the report be accurate? Pharmacogenomic associations in peptide research are still being catalogued. The report will reflect the state of published evidence, clearly flag which associations are strongly established versus still emerging, and will be updated as the literature matures.

When is this launching? We are working toward a limited release for waitlist subscribers first, followed by broader availability. Subscribe below and you will be the first to know.

While the DNA report is being built, the best way to reduce peptide trial-and-error is to understand the mechanism of each compound you are considering.

For the mitochondrial peptides where gene variants matter most, see our SS-31 guide at /guides/ss-31-elamipretide-mitochondrial-peptide and MOTS-c guide at /guides/mots-c-exercise-mimetic-peptide.

For the Russian longevity tradition and what the long-form clinical data actually shows, see our Epithalon guide at /guides/epithalon-telomere-khavinson-peptide.

For a grounded look at the kisspeptin–reproductive axis where MC4R-family variants also matter, see /guides/kisspeptin-intro.

For vendor information in the meantime, our rated suppliers are at /vendors.

This guide is for educational and informational purposes only and does not constitute medical advice. The Peptide DNA Report is an informational product and is not a regulated pharmacogenomic clinical test. Pharmacogenomic associations shift probabilities of response; they do not determine outcomes. Individual response to any peptide depends on many factors beyond genetics including dose, purity, underlying health, and concurrent medications. Any peptide protocol should be discussed with a qualified healthcare professional. DNA data is sensitive personal information and should only be uploaded to services with clear, published privacy policies.